Antiviral drug resistance.
作者信息
Pillay D, Zambon M
机构信息
Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham B15 2TT.
出版信息
BMJ. 1998 Sep 5;317(7159):660-2. doi: 10.1136/bmj.317.7159.660.
Abstract
摘要
相似文献
1
Antiviral drug resistance.
BMJ. 1998 Sep 5;317(7159):660-2. doi: 10.1136/bmj.317.7159.660.
2
[Viruses and antiviral drug resistance].[病毒与抗病毒药物耐药性]
Duodecim. 2002;118(9):911-8.
3
Summary of the III International Consensus Symposium on Combined Antiviral Therapy.第三届联合抗病毒治疗国际共识研讨会综述
Antiviral Res. 1998 May;38(2):75-93. doi: 10.1016/s0166-3542(98)00021-7.
4
[Etiotropic drug therapy of widespread and socially significant human viral infections].[人类广泛且具有社会意义的病毒感染的病因特异性药物治疗]
Antibiot Khimioter. 2010;55(3-4):29-34.
5
[Etiotropic medicinal therapy of viral infections].[病毒感染的病因特异性药物治疗]
Vopr Virusol. 2004 May-Jun;49(3):35-40.
6
Antiviral therapies in children: has their time arrived?儿童抗病毒疗法：其时代已经到来了吗？
Pediatr Clin North Am. 2005 Jun;52(3):837-67, vii. doi: 10.1016/j.pcl.2005.02.006.
7
Quo vadis antiviral agents for herpes, influenza and HIV?治疗疱疹、流感和艾滋病毒的抗病毒药物将何去何从？
J Med Microbiol. 1995 Jul;43(1):1-3. doi: 10.1099/00222615-43-1-1.
8
Part XIV. Antiviral agents other than antiretrovirals: therapy for herpesvirus infections, viral hepatitis, and influenza.第十四部分。抗逆转录病毒药物以外的抗病毒药物：用于治疗疱疹病毒感染、病毒性肝炎和流感。
J Okla State Med Assoc. 2007 Oct;100(10):388-95.
9
[Progress in chemotherapeutic agents--antiviral agents].
Nihon Rinsho. 1986 Apr;44(4):852-7.
10
[Antiviral therapy: from influenza to Pfeiffer's disease].[抗病毒治疗：从流感到 Pfeiffer 病]
Internist (Berl). 2006 Dec;47(12):1245-50. doi: 10.1007/s00108-006-1721-9.
引用本文的文献
1
Targeting Key Stages of the Viral Entry and Life Cycle: A Comprehensive Overview of the Mechanisms of Antiviral Actions.靶向病毒进入和生命周期的关键阶段：抗病毒作用机制的全面概述
Methods Mol Biol. 2025;2927:259-286. doi: 10.1007/978-1-0716-4546-8_15.
2
Exploiting host kinases to combat dengue virus infection and disease.利用宿主激酶对抗登革病毒感染及疾病。
Antiviral Res. 2025 May 8;241:106172. doi: 10.1016/j.antiviral.2025.106172.
3
p38-MAPK is prerequisite for the synthesis of SARS-CoV-2 protein.p38丝裂原活化蛋白激酶是严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白质合成的先决条件。
Virusdisease. 2024 Jun;35(2):329-337. doi: 10.1007/s13337-024-00873-y. Epub 2024 May 27.
4
Promising Potential of Curcumin and Related Compounds for Antiviral Drug Discovery.姜黄素和相关化合物在抗病毒药物发现方面的广阔前景。
Med Chem. 2024;20(6):597-612. doi: 10.2174/0115734064277371240325105016.
5
Cathelicidin peptide analogues inhibit EV71 infection through blocking viral entry and uncoating.cathelicidin肽类似物通过阻断病毒进入和脱壳来抑制肠道病毒71型（EV71）感染。
PLoS Pathog. 2024 Jan 25;20(1):e1011967. doi: 10.1371/journal.ppat.1011967. eCollection 2024 Jan.
6
Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.病原体中抗菌药物耐药性的扩展：当前缓解策略及创新疗法进展综述
JAC Antimicrob Resist. 2023 Dec 11;5(6):dlad127. doi: 10.1093/jacamr/dlad127. eCollection 2023 Dec.
7
Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir.SARS-CoV-2 核糖核酸结合部位的灵活性增加导致对瑞德西韦的耐药性。
PLoS Pathog. 2023 Mar 27;19(3):e1011231. doi: 10.1371/journal.ppat.1011231. eCollection 2023 Mar.
8
Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide.硝唑尼特治疗的两名共济失调毛细血管扩张症患者肉芽肿病变中疫苗衍生风疹病毒的药物敏感性及准种进化
Pathogens. 2022 Mar 11;11(3):338. doi: 10.3390/pathogens11030338.
9
Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment.污水中抗 COVID-19 药物的可疑筛查：对水生态环境的潜在不良影响。
Sci Total Environ. 2022 Jun 10;824:153756. doi: 10.1016/j.scitotenv.2022.153756. Epub 2022 Feb 11.
10
Nanomedicine to fight infectious disease.纳米医学对抗传染病。
Adv Drug Deliv Rev. 2021 Dec;179:113996. doi: 10.1016/j.addr.2021.113996. Epub 2021 Oct 8.
本文引用的文献
1
Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV.
Commun Dis Public Health. 1998 Mar;1(1):5-13.
2
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.对多种逆转录酶和蛋白酶抑制剂耐药的HIV-1变异株的性传播。
N Engl J Med. 1998 Jul 30;339(5):307-11. doi: 10.1056/NEJM199807303390504.
3
Audit of HIV RNA quantitation measurements in the West Midlands: a preliminary report. Collaborating HIV Physicians.
Int J STD AIDS. 1998 Jun;9(6):361-3. doi: 10.1258/0956462981922287.
4
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.拉米夫定治疗慢性乙型肝炎的一年期试验。亚洲肝炎拉米夫定研究组。
N Engl J Med. 1998 Jul 9;339(2):61-8. doi: 10.1056/NEJM199807093390201.
5
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.成人HIV感染者的抗逆转录病毒药物耐药性检测：对临床管理的影响。国际艾滋病学会美国小组。
JAMA. 1998 Jun 24;279(24):1984-91. doi: 10.1001/jama.279.24.1984.
6
Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.接受更昔洛韦维持治疗视网膜炎的患者的巨细胞病毒聚合酶链反应病毒血症
AIDS. 1998 Apr 16;12(6):605-11. doi: 10.1097/00002030-199806000-00009.
7
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.口服流感病毒神经氨酸酶抑制剂GS 4071的前体药物可保护小鼠和雪貂免受流感感染。
Antimicrob Agents Chemother. 1998 Mar;42(3):640-6. doi: 10.1128/AAC.42.3.640.
8
9
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.神经氨酸酶抑制剂扎那米韦治疗流感病毒感染的疗效和安全性。GG167流感研究小组。
N Engl J Med. 1997 Sep 25;337(13):874-80. doi: 10.1056/NEJM199709253371302.
10
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
J Infect Dis. 1997 Jun;175(6):1502-6. doi: 10.1086/516487.
Zotero 插件